Maze Therapeutics, Inc. (MAZE) Stock Analysis

Q: What is the MAZE stock price target?

Take-profit $54.81 (+114.4% upside). Prior stop was $24.06.

Q: What are the risks of investing in MAZE?

Concentration risk — Pipeline: MZE829; Quality below floor (3.4 < 4.0); Quality below floor (3.4 < 4.0).

Q: Is MAZE overvalued or undervalued?

Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about MAZE?

12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $63.

SellModerate ConfidenceUpdated 3 days ago (May 18, 2026, 12:51 AM ET)

Healthcare · Biotechnology

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases using its Compass genetics platform. Its two lead programs—MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (Phase 2 ready... Read more

$25.56+114.4% A.UpsideScore 5.3/10#68 of 157 Biotechnology

QualityF-score5 / 9FCF yield-5.78%

Stop $24.06Target $54.81(analyst − 13%)A.R:R 10.6:1

Analyst target$63.00+146.5%11 analysts

$54.81our TP

$25.56price

$63.00mean

$110

Sell if holding. Engine safety override at $25.56: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 87d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

Recent Developments — Maze Therapeutics, Inc.

Latest news

Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate — benzinga May 12, 2026 positive
Maze Therapeutics Prices $150M Offering Of 5.54M Common Shares At $23.50 And 850K Pre-Funded Warrants At $23.499 — benzinga Apr 22, 2026 negative
Truist Securities Maintains Buy on Maze Therapeutics, Lowers Price Target to $64 — benzinga Apr 14, 2026 neutral

Generated 2026-05-20T21:56:22Z.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: MZE829

Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.9

Mkt Cap$1.4B

EV/EBITDA-8.5

Profit Mgn0.0%

ROE-38.7%

Rev Growth—

Beta—

DividendNone

Rating analysts12

Quality Signals

Piotroski F5/9MoatNarrow

Concentration Risks(10-K Item 1A)

HIGHpipelineMZE829
10-K Item 1A: 'We initiated a Phase 2 trial of MZE829, our most advanced lead program, in November 2024, dosed our first patient in February 2025 and reported positive topline clinical proof of concept data in March 2026'

Material Events(8-K, last 90d)

2026-03-25Item 5.02LOW
Board appointed Neil Kumar (co-founder and CEO of BridgeBio Pharma) as a Class I director effective March 27, 2026. No officer departures.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality3.415%0.51

Growth5.015%0.75

Momentum5.510%0.55

Sentiment8.410%0.84

Insider Activity3.510%0.35

Peer Rank2.310%0.23

Technical Setup5.65%0.28

Risk Profile5.25%0.26

Catalyst3.75%0.19

Overall (Σ contributions)5.30

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank

0.6

Quality Rank

3.7

Growth Rank

5.0

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Current Ratio

5.0

Piotroski F

5.6

Moat

6.2

Gross Margin

10.0

Cash-burning: FCF -409% of revenue

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.0

Earnings History

3.3

Erm

5.0

Earnings Timing

5.0

News Activity

5.0

Earnings concerns: 2B/2M

GatesMomentum 5.5>=5.5A.R:R 10.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 87d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

44 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $24.80Resistance $29.09

Price Targets

$24

$55

A.Upside+114.4%

A.R:R10.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)

Earnings

2/4 beats

Next Earnings2026-08-12 (87d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is MAZE stock a buy right now?

Sell if holding. Engine safety override at $25.56: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $24.06. Score 5.3/10, moderate confidence.

What is the MAZE stock price target?

Take-profit target: $54.81 (+114.4% upside). Prior stop was $24.06. Stop-loss: $24.06.

What are the risks of investing in MAZE?

Concentration risk — Pipeline: MZE829; Quality below floor (3.4 < 4.0).

Is MAZE overvalued or undervalued?

Maze Therapeutics, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about MAZE?

12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $63.

What does Maze Therapeutics, Inc. do?Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for...